Literature DB >> 6303108

Neuron-specific enolase in neuroendocrine tumors of the thymus, bronchus, and skin.

M R Wick, B W Scheithauer, K Kovacs.   

Abstract

In order to better define the use of neuron-specific enolase (NSE) as a marker for neuroendocrine neoplasms, we studied 11 thymic carcinoid tumors, three bronchial small-cell carcinomas (all with cutaneous metastases), and 10 trabecular carcinomas of the skin for its presence, using the peroxidase-antiperoxidase (PAP) technic with an antiserum directed at NSE. All 11 carcinoid tumors stained positively, as did two of the bronchial small-cell carcinomas and seven of the trabecular carcinomas. We conclude that PAP staining for NSE content may be a useful adjunct to morphologic analysis in diagnostically identifying the tumors we studied and that our results support the concept of a functionally unified APUD system, as reflected in the tumors originating from it. Nevertheless, because of the vagaries of the PAP method, exemplified by the results in our small series, it cannot be relied upon as a sole indicator that a tumor contains NSE and is therefore neuroendocrine. Also, since it is hypothesized that NSE is present in all tumors of this type, staining for its presence would seem to be of little benefit in distinguishing primary from secondary neuroendocrine tumors or in identifying the origin of metastatic lesions that have a neuroendocrine histologic appearance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6303108     DOI: 10.1093/ajcp/79.6.703

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  17 in total

1.  Langerhans cells can express neuron-specific enolase immunoreactivity.

Authors:  F Fantini; C Pincelli; C Sevignani; A Baraldi; A Giannetti
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

2.  Merkel cell (small cell) carcinoma of the skin: immunohistochemical and ultrastructural demonstration of distinctive perinuclear cytokeratin aggregates and a possible association with B cell neoplasms.

Authors:  F P Kuhajda; J L Olson; R B Mann
Journal:  Histochem J       Date:  1986-05

3.  Carcinoid tumors of the thymus.

Authors:  S Venkatesh; N A Samaan
Journal:  West J Med       Date:  1990-01

4.  Unexpected thymic hyperplasia in transgenic mice harboring a neuronal promoter fused with simian virus 40 large T antigen.

Authors:  F M Botteri; H van der Putten; D F Wong; C A Sauvage; R M Evans
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

Review 5.  Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system.

Authors:  G Reifenberger; J Szymas; W Wechsler
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

Review 6.  The correlation of neoplastic vulnerability with central neuroepithelial cytogeny and glioma differentiation.

Authors:  L J Rubinstein
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

7.  Subependymal giant cell astrocytoma. Significance and possible cytogenetic implications of an immunohistochemical study.

Authors:  J M Bonnin; L J Rubinstein; S C Papasozomenos; P J Marangos
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

8.  Antineuron specific enolase staining reactions in sarcomas and carcinomas: its lack of neuroendocrine specificity.

Authors:  M Leader; M Collins; J Patel; K Henry
Journal:  J Clin Pathol       Date:  1986-11       Impact factor: 3.411

9.  Gastrin-releasing peptide, a mammalian analog of bombesin, is present in human neuroendocrine lung tumors.

Authors:  D G Bostwick; K A Roth; C J Evans; J D Barchas; K G Bensch
Journal:  Am J Pathol       Date:  1984-11       Impact factor: 4.307

10.  Small cell neuroendocrine (oat cell) carcinoma of the male breast. Immunocytochemical and ultrastructural investigations.

Authors:  G Jundt; A Schulz; P U Heitz; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.